Last updated: August 28, 2026
Daxxify (daxibotulinumtoxinA-lanm) represents a notable advancement in the field of neurotoxin treatments, and recent clinical trial activity suggests the medication’s potential may extend well beyond its current approved uses. A Phase 2a study now recruiting participants is evaluating DaxibotulinumtoxinA-lanm for dynamic forehead lines and glabellar lines, while a separate Phase 4 trial is investigating effects for blepharospasm and hemifacial spasm. For patients in the Portland metro area seeking effective wrinkle reduction, understanding these developments offers insight into how treatment options may evolve. Vip MediSpa in Tigard provides Daxxify injections and remains a resource for patients interested in exploring current and emerging neurotoxin possibilities.
What Is DaxibotulinumtoxinA-lanm (Daxxify)?
DaxibotulinumtoxinA-lanm serves as the active pharmaceutical ingredient in the Daxxify injectable treatment. This botulinum neurotoxin type A formulation has been engineered to address dynamic wrinkles caused by repeated muscle contractions. The medication works by temporarily blocking the nerve signals that trigger muscle activity, allowing the overlying skin to smooth and reducing the appearance of lines and creases.
How does Daxxify differ from other neurotoxins like Botox?
While all FDA-approved neurotoxins contain botulinum toxin type A, each formulation possesses distinct characteristics that influence clinical performance. The manufacturing processes, purification methods, and potency determination standards vary between products, meaning that unit doses are not interchangeable across different neurotoxin brands. This product-specific profile means that dosing and injection approaches must be tailored to each formulation individually, rather than applying conversion ratios between products.
What makes Daxxify’s peptide formulation unique?
The Daxxify formulation incorporates a peptide excipient designed to stabilize the neurotoxin molecule. This stabilizing component distinguishes the medication from traditional neurotoxin preparations. The peptide technology represents an engineering approach aimed at supporting the medication’s activity profile, and it reflects Revance Therapeutics’ specific approach to neurotoxin development.
What New Daxxify Clinical Trials Are Underway?
Revance Therapeutics has advanced two clinical trials that expand the investigation of DaxibotulinumtoxinA-lanm into additional therapeutic areas. These studies represent active development of the medication’s potential applications beyond current approvals.
What is the Phase 2a trial (NCT06411002) studying?
The Phase 2a study registered as NCT06411002 is currently evaluating DaxibotulinumtoxinA-lanm for the treatment of dynamic forehead lines and glabellar lines. This investigation focuses specifically on aesthetic applications that build upon the medication’s existing approval profile. The trial represents Revance’s continued investment in understanding how their formulation performs across different treatment areas within cosmetic medicine.
How does the blepharospasm trial (NCT06195241) expand Daxxify’s scope?
A separate trial registered as NCT06195241 is studying DaxibotulinumtoxinA-lanm for the treatment of blepharospasm and hemifacial spasm. This Phase 4 study lists Montefiore Medical Center as the lead sponsor, with an estimated enrollment of 40 participants. The trial initiated in February 2025 with an estimated completion date in March 2027. By investigating therapeutic neurological applications, this study broadens the medication’s development beyond aesthetic uses into movement disorder management.
What Conditions Is Daxxify Currently FDA Approved to Treat?
Understanding the current approved uses of Daxxify provides important context for appreciating the significance of the ongoing clinical trials. The medication holds specific FDA approvals that establish its baseline safety and efficacy profile for particular indications.
Is Daxxify currently FDA approved for forehead lines?
Daxxify received FDA approval for the treatment of glabellar lines, commonly known as frown lines between the eyebrows. The medication’s approval pathway established its safety and efficacy for this aesthetic indication, though forehead lines specifically remain under investigation in the current Phase 2a trial. Patients seeking forehead treatment should understand that this area is being actively studied but does not yet represent an approved indication.
How long has Daxxify been available for aesthetic use?
Daxxify represents a relatively recent addition to the portfolio of available neurotoxin treatments. The medication entered the aesthetic market offering an alternative option for patients and providers exploring neurotoxin therapy for approved indications. Its availability has provided Portland-area patients with another choice when considering injectable wrinkle treatments.
How Might Daxxify’s Clinical Development Affect Future Treatment Options?
The expansion of clinical research into additional treatment areas signals potential evolution in how DaxibotulinumtoxinA-lanm may serve patients in the future. These development activities suggest Revance’s commitment to exploring the full scope of their formulation’s capabilities.
What other areas beyond approved uses is Revance researching?
Beyond the forehead and glabellar line investigation, Revance’s clinical program continues to evaluate DaxibotulinumtoxinA-lanm across both aesthetic and therapeutic applications. The blepharospasm study reflects interest in neurological movement disorders, while the aesthetic trials address cosmetic concerns such as crow’s feet, neck bands, bunny lines, and lip lines that patients frequently inquire about. Botulinum neurotoxin treatments have demonstrated versatility across numerous facial and neck areas, and continued research may expand the understanding of optimal approaches for various treatment zones.
Could Daxxify address neck bands, bunny lines, or other concerns?
Botulinum neurotoxin products have established utility across a broad range of aesthetic applications, including treatment of dynamic wrinkles in areas such as the peri-orbital region, nasal rhytides (bunny lines), perioral zone, and neck. The specific role of DaxibotulinumtoxinA-lanm in these applications will depend on future clinical data and regulatory approval decisions. Patients interested in multiple treatment areas benefit from consulting with providers experienced in neurotoxin techniques who can discuss the current evidence and emerging possibilities.
What Should Tigard Patients Know About Daxxify Availability?
For patients in the Tigard area and surrounding Portland metro communities including Beaverton, Lake Oswego, and Happy Valley, accessing current Daxxify treatments involves understanding what is available today while remaining aware of how the clinical landscape continues to develop.
Where can Portland-area patients access Daxxify treatments?
Vip MediSpa in Tigard provides Daxxify injections for patients within the Portland metro area, serving communities such as Milwaukie, West Linn, Durham, and Maywood Park. Vancouver-area patients and those from Fairview also have access to the clinic’s neurotoxin services. The clinic offers consultations where patients can discuss whether Daxxify aligns with their aesthetic goals and receive personalized treatment recommendations based on their individual needs.
How does staying informed about clinical developments help treatment planning?
Understanding the ongoing clinical trial activity helps patients appreciate that neurotoxin treatments continue to evolve and improve. Staying aware of research developments enables informed conversations with healthcare providers about treatment options, expected outcomes, and potential future possibilities. Patients who approach their aesthetic care with knowledge of the broader clinical landscape position themselves to make decisions aligned with both current best practices and emerging evidence.
Why Daxxify Clinical Trials Matter for Portland Patients
The Phase 2a trial for forehead lines and the Phase 4 blepharospasm study represent meaningful clinical development activity for DaxibotulinumtoxinA-lanm. These investigations expand understanding of the formulation’s potential across aesthetic and therapeutic applications. For Portland-area patients exploring neurotoxin options, this ongoing research reflects a commitment to advancing treatment possibilities. Those interested in learning more about current Daxxify treatments or discussing how emerging clinical data might inform their care are encouraged to schedule a consultation at Vip MediSpa.
Frequently Asked Questions
What is Daxxify and how does it work?
Daxxify (daxibotulinumtoxinA-lanm) is an FDA-approved neurotoxin treatment that addresses dynamic wrinkles caused by repeated muscle contractions. It works by temporarily blocking the nerve signals that trigger muscle activity, allowing the overlying skin to smooth and reducing the appearance of lines and creases. The formulation includes a unique peptide excipient designed to stabilize the neurotoxin molecule.
What new Daxxify clinical trials are currently underway?
Two active trials are investigating DaxibotulinumtoxinA-lanm. A Phase 2a trial (NCT06411002) is evaluating the treatment for dynamic forehead lines and glabellar lines. A separate Phase 4 trial (NCT06195241) sponsored by Montefiore Medical Center is studying effects for blepharospasm and hemifacial spasm, with 40 participants and an estimated completion date of March 2027.
What is Daxxify currently FDA approved to treat?
Daxxify received FDA approval specifically for treating glabellar lines – the frown lines between the eyebrows. Forehead lines remain under investigation in the current Phase 2a trial and do not yet represent an approved indication. Patients should understand that treatment for forehead lines is being actively studied but requires separate regulatory approval.
How is Daxxify different from other neurotoxins like Botox?
While all FDA-approved neurotoxins contain botulinum toxin type A, each formulation has distinct characteristics that influence clinical performance. The manufacturing processes, purification methods, and potency determination standards vary between products, meaning unit doses are not interchangeable across different neurotoxin brands. Dosing and injection approaches must be tailored to each formulation individually.
Where can Portland-area patients receive Daxxify treatments?
Vip MediSpa in Tigard provides Daxxify injections for patients throughout the Portland metro area, including Beaverton, Lake Oswego, Happy Valley, Milwaukie, West Linn, Durham, Maywood Park, Vancouver, and Fairview. The clinic offers consultations where patients can discuss whether Daxxify aligns with their aesthetic goals and receive personalized treatment recommendations.
What other treatment areas might Daxxify potentially address in the future?
Botulinum neurotoxin products have established utility across numerous aesthetic applications including crow’s feet, neck bands, bunny lines, and lip lines. Revance’s clinical program continues evaluating DaxibotulinumtoxinA-lanm for both aesthetic and therapeutic applications. The specific role of this formulation in these additional areas will depend on future clinical data and regulatory approval decisions.
Why should patients stay informed about Daxxify clinical developments?
Understanding ongoing clinical trial activity helps patients appreciate that neurotoxin treatments continue to evolve and improve. Staying aware of research developments enables informed conversations with healthcare providers about treatment options, expected outcomes, and potential future possibilities. Patients who understand the broader clinical landscape position themselves to make decisions aligned with both current best practices and emerging evidence.
